Your browser doesn't support javascript.
loading
Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
Liang, Sixian; Peng, Xun; Li, Xiaoli; Yang, Ping; Xie, Linhao; Li, Yaochen; Du, Caiwen; Zhang, Guojun.
Affiliation
  • Liang S; Department of Breast Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China.
  • Peng X; These authors have contributed equally to this work.
  • Li X; Department of Radiotherapy, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China.
  • Yang P; These authors have contributed equally to this work.
  • Xie L; Department of Breast Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China.
  • Li Y; Department of Breast Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China.
  • Du C; Department of Breast Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China.
  • Zhang G; The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China.
Oncotarget ; 13: 583-584, 2022.
Article in En | MEDLINE | ID: mdl-35391718
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncotarget Year: 2022 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncotarget Year: 2022 Document type: Article